JJ
PTGX icon

Johnson & Johnson’s Protagonist Therapeutics PTGX Stock Holding History

Johnson & Johnson’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258M Hold
2,449,183
– – 39.57% 1
2025
Q4 		$214M Hold
2,449,183
– – 38.54% 1
2025
Q3 		$163M Hold
2,449,183
– – 32.29% 1
2025
Q2 		$136M Hold
2,449,183
– – 40.83% 1
2025
Q1 		$118M Hold
2,449,183
– – 34.65% 1
2024
Q4 		$94.5M Hold
2,449,183
– – 24.48% 1
2024
Q3 		$110M Hold
2,449,183
– – 25.79% 1
2024
Q2 		$84.9M Hold
2,449,183
– – 21.18% 1
2024
Q1 		$70.9M Hold
2,449,183
– – 1.61% 4
2023
Q4 		$56.2M Hold
2,449,183
– – 1.28% 3
2023
Q3 		$40.9M Hold
2,449,183
– – 15.05% 3
2023
Q2 		$67.6M Hold
2,449,183
– – 21% 1
2023
Q1 		$56.3M Hold
2,449,183
– – 18.32% 2
2022
Q4 		$26.7M Hold
2,449,183
– – 7.77% 5
2022
Q3 		$20.6M Hold
2,449,183
– – 6.08% 6
2022
Q2 		$19.4M Hold
2,449,183
– – 4.95% 8
2022
Q1 		$58M Hold
2,449,183
– – 10.96% 3
2021
Q4 		$83.8M Hold
2,449,183
– – 9.54% 3
2021
Q3 		$43.4M Buy
+2,449,183
New +$104M 3.81% 7

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Johnson & Johnson's PTGX Position: Q1 2026 in Review

Johnson & Johnson held its Protagonist Therapeutics (PTGX) position steady in Q1 2026 at 2,449,183 shares worth $258M. The position accounts for 39.57% of the portfolio, ranked #1.

Johnson & Johnson first reported a position in PTGX in Q3 2021 and has held it in 19 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Johnson & Johnson held 2,449,183 shares of Protagonist Therapeutics worth $258M as of Q1 2026.
  • Johnson & Johnson left its Protagonist Therapeutics share count unchanged in Q1 2026.
  • Protagonist Therapeutics made up 39.57% of Johnson & Johnson's portfolio in Q1 2026, its #1 holding.
  • Johnson & Johnson first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Johnson & Johnson's 13F filing for Q1 2026, filed 13 May 2026.